In silico cancer research towards 3R

Abstract

BackgroundImproving our understanding of cancer and other complex diseases requires integrating diverse data sets and algorithms. Intertwining in vivo and in vitro data and in silico models are paramount to overcome intrinsic difficulties given by data complexity. Importantly, this approach also helps to uncover underlying molecular mechanisms. Over the years, research has introduced multiple biochemical and computational methods to study the disease, many of which require animal experiments. However, modeling systems and the comparison of cellular processes in both eukaryotes and prokaryotes help to understand specific aspects of uncontrolled cell growth, eventually leading to improved planning of future experiments. According to the principles for humane techniques milestones in alternative animal testing involve in vitro methods such as cell-based models and microfluidic chips, as well as clinical tests of microdosing and imaging. Up-to-date, the range of alternative methods has expanded towards computational approaches, based on the use of information from past in vitro and in vivo experiments. In fact, in silico techniques are often underrated but can be vital to understanding fundamental processes in cancer. They can rival accuracy of biological assays, and they can provide essential focus and direction to reduce experimental cost.Main bodyWe give an overview on in vivo, in vitro and in silico methods used in cancer research. Common models as cell-lines, xenografts, or genetically modified rodents reflect relevant pathological processes to a different degree, but can not replicate the full spectrum of human disease. There is an increasing importance of computational biology, advancing from the task of assisting biological analysis with network biology approaches as the basis for understanding a cell’s functional organization up to model building for predictive systems.ConclusionUnderlining and extending the in silico approach with respect to the 3Rs for replacement, reduction and refinement will lead cancer research towards efficient and effective precision medicine. Therefore, we suggest refined translational models and testing methods based on integrative analyses and the incorporation of computational biology within cancer research.

The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models

“…The continuing increase in the knowledge about mesothelial carcinogenesis will permit the use of more pertinent cell models that represent the MM tumor. New approaches not yet used in MM should be explored, including organ-on-a-chip technologies or in silico biological systems using computational modeling and machine learning (120,121). Powerful technological tools should allow researchers to establish models with MM cells that grow in a more accurate tumor microenvironment, and possible in situ molecular analyses of tumor cells.…”

Open Data for Differential Network Analysis in Glioma

“…There are a wide range of datasets available open for data mining, predictive modeling or other purposes [4]. Obtainable data enable many hypotheses to be tested in silico, saving time and money, and maximizing efficiency [5]. Various data resources can be of interest including biomolecular repository hubs, additionally, offering not exclusively upload and analysis options or links to publications.…”

Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective

“…Moreover, many of these showings and evaluations are performed utilizing conventional cell lines which only represent the actual tumor in the persons, leaving the entire heterogeneity of the intra- and inter-tumors benefit of the entire. Among the most pivotal role in the development of biological diagnostics of effects and treatment interventions for tumor has promptly developed suitable results to replace variable and expensive in vivo models (Jean-Quartier et al., 2018 ).…”